021-58383963

 

 

 

 

 

 

 

 

About us

 

 

 

 

 

 

公司介绍

 Shanghai Best-Link Bioscience

图片展示

 

   Shanghai Best-Link Bioscience LLC was founded in 2021 and is a high-tech enterprise engaged in innovative drug research and development. Best-Link focuses on the development of novel nano-conjugate drugs and precise nano-drug delivery platforms based on advanced conjugation technology and nanotechnology to develop innovative drugs for precision cancer treatment and tumor immunotherapy. Best-Link adheres to the concept of "Benefiting the people and leading the future", and is committed to developing innovative drugs with better therapeutic effects, less toxic side effects, and better compliance.  

 

图片展示
图片展示
图片展示

Founded in 2021

图片展示
图片展示

200台

出口销售数量

图片展示

2,000 square meters of office space

Benefiting the People and Leading the Future

 

Best-Link first proposed the concept of "Nano-Train Conjugate Drugs", which can effectively deliver conjugate drugs into the tumor microenvironment and selectively release their active payloads at a fixed time and location by controlling the delivery process. The active payloads released from the tumor microenvironment can penetrate effectively and deeply into the tumor, causing sustained damage to the tumor. Based on this concept, Best-Link has developed a novel nano-conjugate drug platform (NMPDC®) by integrating conjugation technology and nanotechnology. By effectively controlling the nano-conjugate’s particle size, charge, and release time and position, it has been addressed two key issues of ADC drugs: low delivery efficiency and low permeability.

 

Management Team

图片展示
图片展示

 
•Education
•Ph. D. (Polymer Science) of Zhejiang University
•Ph. D. (Organic Chemistry) of The Hong Kong Polytechnic University
•Visiting scholar at RWTH Aachen University, Germany
•Postdoctoral Fellow of Department of Chemistry and Chemical Biology, Harvard University (Advisor: Professor E. J. Corey)
• Professional Work Experience
•Principal scientist at Eli Lilly and Company, engaged in the new drug R&D and new drug CMC
•Entrepreneurial Experience
•Co-founder of Shanghai Unitris Biopharma Co., Ltd (Hengrui)
•Co-founder of Shanghai Selection Bioscience LLC (Qingfeng)
•CEO, founder and general manager of Shanghai Best-Link Bioscience LLC
•Drug Development Achievements
•4 in clinical (HER2-ADC, cMet-ADC, BISNP-BL0006, NMPDC-BL0020)
•1 new drug was approved (Tenofovir Amibufenamide was approved in June)
•10 generic drugs were approved: Sevoflurane, Eribulin (The only China-developed eribulin generic product was approved by FDA to enter the U.S. market, with more than 80 steps of total synthesis), caspofungin, paricalcitol, tafloprost, gadobutrol, docetaxel, irinotecan, fondaparin, abriaterone

 

 

图片展示
图片展示

 
•Education
•Published over 20 papers in the international journals
•MD of Soochow University
•Ph. D. in Biology of The Hong Kong Polytechnic University
•Conducted clinical practice and basic research at Affiliated Hospital of Zhejiang University, Boston University School of Medicine, Indiana University School of Medicine, and University of Florida School of Medicine in the United States
•Professional Work Experience
•More than 20 years experience of clinical R&D and drug registration
•Served as Clinical Medical Director at Jiangsu Hengrui Pharmaceutical Co., Ltd, Vice President of Wuxi PRA, Vice President & CMO of Qingfeng Pharmaceutical Co., Ltd,  CMO of Zhejiang Yangshengtang and Deputy Director of the Natural Medicine Research Institute of Yangshengtang
•Led multiple national and provincial-level major projects: 6 NDA (Apatinib Mesylate, Morinidazole, Polyethylene Glycol GCSF, Retagliptin, Flumatinib, and Polyethylene Glycol Losenatide)
•Successfully completed 10 ANDA and 40+ IND applications

 




 

 

 
成员介绍
在线客服
联系方式
热线电话
400-12346578
上班时间
周一到周五
在线客服
添加微信好友,详细了解产品
使用企业微信
“扫一扫”加入群聊
复制成功!
添加微信好友,详细了解产品
我知道了